Although all major subsets of DCs are critical components of anti-tumor immunity, Irf8- and Batf3-dependent cDC1 (Xcr1+CD103+) lineage is specialized for antigen cross-presentation with MHC class I (MHCI) molecules to activate CD8+ T cells [8]. The gene discussed is CD8A; the disease is neoplasm.